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Abstract  19 
Purpose:  Augmented microfracture techniques use growth factors, cells and/or scaffolds to 20 
enhance the healing of microfracture treated cartilage defects. This study investigates the 21 
effect of delivering recombinant human fibroblastic growth factor 18 (rhFHF18, Sprifermin) 22 
via a collagen membrane on the healing of a chondral defect treated with microfracture in an 23 
ovine model. Methods:  8mm diameter chondral defects were created in the medial femoral 24 
condyle of 40 sheep (n=5/treatment group).  Defects were treated with microfracture alone, 25 
microfracture + intra-articular rhFGF18 or microfracture + rhFGF-18 delivered on a 26 
membrane. Outcome measures included mechanical testing, weight bearing, International 27 
Cartilage Repair Society repair score, modified O’Driscoll score, qualitative histology and 28 
immunohistochemistry for types I and II collagen.  Results: In animals treated with 32g 29 
rhFGF-18 + membrane and intra-articularly there was a statistically significant improvement 30 
in weight bearing at 2 and 4 weeks post surgery and in the modified O’Driscoll score 31 
compared to controls.  In addition repair tissue stained was more strongly stained for type II 32 
collagen than for type I collagen. Conclusion:  rhFGF-18 delivered via a collagen membrane 33 
at the point of surgery potentiates the healing of a microfracture treated cartilage defect.  34 
 35 
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 37 
Introduction  38 
Microfracture, first described by Steadman et al [1,2], permits bone marrow derived 39 
mesenchymal stem and progenitor cells into a chondral defect site [3]  by making small holes 40 
through the subchondral bone plate to access the underlying subchondral bone marrow [4].  41 
3 
 
The progenitor cells have a multipotent differentiation capacity that includes the ability to 42 
form cells of the chondrocyte lineage; this differentiation capacity produces a cartilaginous 43 
repair tissue at the site of the defect. Of the many different surgical procedures which are in 44 
routine use worldwide in order to promote articular cartilage healing, microfracture is 45 
commonly performed [5] and often advocated as a first line of treatment for cartilage defect 46 
repair [6]. 47 
In the joint, bones are surfaced with hyaline cartilage. Whilst a number of treatment methods 48 
stimulate cartilage repair at the site of defects, the type of the repair tissue is crucial for 49 
restoration of normal joint function, with improved patient outcome directly correlated with 50 
repair tissue quality [7,8]. In microfracture healed defects, the initial tissue formed is 51 
granulation tissue which becomes replaced with fibrous repair tissue [4], biochemically and 52 
mechanically inferior to hyaline cartilage.  Continuous loading of the fibrocartilagenous 53 
repair leads to degeneration of the repair tissue [9], with deteriorating results following 54 
microfracture at 24 month second-look arthroscopy and biopsy [8].  Thus, one goal of 55 
improving the efficacy of microfracture is to modify the repair tissue produced.  A number of 56 
different strategies have been reported including the use of growth factors in combination 57 
with microfracture [10] in animal models – one example of an ‘augmented microfracture’ 58 
strategy. Growth factors used have included the bone morphogenic proteins (BMPs)[11,12], 59 
transforming growth factors (TGF-βs) [13] and platelet rich plasma (PRP) [14], with and 60 
without biomaterials [15]. Recently, our group reported significantly improved healing of a 61 
microfracture treated large animal chondral defect when intra-articular rhFGF-18 62 
(Sprifermin) was administered post-surgery [16]. 63 
FGF-18 has been reported to be an anabolic growth factor [17,18], promoting 64 
chondrogenesis, osteogenesis and bone and cartilage repair [19-22]. Intra-articular rhFGF-18 65 
has been shown to increase in de novo cartilage formation and reduce osteoarthritis (OA) in 66 
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rat surgical models of OA[23,24]. These results, in combination with our published data[16], 67 
indicate that intra-articular rhFGF18 has the potential to enhance hyaline cartilage repair in 68 
microfracture treatment of cartilage defects.  However, whilst intra-articular injections are an 69 
efficacious treatment method, they are invasive, transiently painful and require repeated 70 
clinic visits for administration, leading to reduced patient compliance.  Indeed, there is an 71 
increasing trend, within the clinic, towards development of ‘one-step articular cartilage 72 
repair’ treatments in order to simplify cartilage defect therapy [25].  The development of a 73 
single step system for the administration of FGF-18 to defects treated by microfracture would 74 
therefore represent a significant improvement over the intra-articular administration of 75 
rhFGF-18. 76 
The purpose of this study was to investigate whether delivering rhFGF-18 via a bilayer 77 
collagen membrane at the point of surgery to a microfracture treated chondral defect would 78 
demonstrate improved articular cartilage repair compared to microfracture alone or rhFGF-18 79 
administered intra-articularly in an ovine chondral defect model. 80 
 81 
Methods 82 
This study received approval from both local research ethics committee and the Home Office.   83 
Animals:  A total of forty skeletally mature female Welsh Mountain Sheep (mean age 3.9 84 
years) were included in the study.  Each sheep weighed between 40 and 42kg at the start of 85 
the experiment with no significant differences in weight between groups.  Each experimental 86 
group contained five sheep.  This number was derived from a Power calculation using the 87 
results from previous similar experiments[16]. 88 
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Experimental design:  For all animals, full thickness chondral defects of 8mm diameter were 89 
created in the medial femoral condyle (MFC) of the right stifle joint. A microfracture awl was 90 
then used to create seven evenly spaced microfracture holes (1.5mm diameter, 3mm deep) in 91 
each defect. Eight experimental groups were created (Table 1).  92 
Surgical technique:  93 
The basic surgical procedure was as described previously [16]. An 8mm diameter chondral 94 
defect was created 10 mm distal to the condyle groove junction and aligned with the medial 95 
crest of the trochlear groove.  96 
rhFGF-18  administration: rhFGF-18 was applied either at point of surgery delivered 97 
adsorbed to a membrane or as intra-articular injections. Previous experiments in our group 98 
had demonstrated a statistically significant effect of 30g rhFGF18 administered intra-99 
articularly [16].  Membrane delivered rhFGF-18: rhFGF-18 was applied to an 8mm 100 
diameter bilayer collagen membrane (Chondrogide, Geistlich) at concentrations between 101 
0.064g and 32g (Table 1). The membrane/growth factor construct was applied to the 102 
chondral defect and glued in place using Tisseel tissue glue at the periphery of the membrane 103 
(Baxter). Intra-articular rhFGF-18 30g rhFGF18 was injected into the medial femoro-104 
tibial joint once a week for 3 weeks at 4, 5 and 6 weeks post-operatively and 16, 17 and 18 105 
weeks post-operatively. 106 
Force plate analysis of weight bearing A force plate (Accusway, AMTI, USA) was used to 107 
quantify the weight bearing of the operated limb.  Weight bearing was measured at a walking 108 
gait prior to surgery, 2 weeks, 4 weeks, 2 months, 3 months, 4 months and 5 months after 109 
surgery. At each time point each animal had 10 recordings acquired and a mean weight 110 
bearing value calculated.  Each measurement was converted into N/kg force and calculated as 111 
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a percentage of weight bearing pre-surgery for each individual animal.  Weight bearing data 112 
was grouped into treatment groups for final analysis. 113 
Necropsy:  Animals were humanely sacrificed at 13 or 26 weeks postoperatively using a 114 
lethal dose of sodium pentobarbital.   115 
Gross Morphology:  The joints were photographed and the surface of the osteochondral 116 
defect sites blindly scored using the International Cartilage Repair Society score (Table 2). 117 
Mechanical testing:  After the gross morphological observations were made, each implant 118 
site underwent non-destructive mechanical testing to determine changes to the cartilage 119 
surface surrounding the implant or empty defect.  Hardness measurements were taken in 120 
duplicate from the centre of the chondral defect, and at a distance of 1 mm inside the original 121 
edge of the created chondral defect at the 12, 3, 6, and 9 o’clock positions, and 1mm from the 122 
edge in the perilesional cartilage, using a handheld digital durometer (Shore S1, M scale, 123 
Instron Ltd, UK).   A number between 0-100 would be given with an inbuilt calibrated error 124 
of +/-5.  These measurements were then repeated in the contralateral limb in the same 125 
anatomic sites giving a surrogate measure of hardness of the reparative tissue by expressing 126 
the result as a percentage relative to the control cartilage in the contralateral limb, and the 127 
perilesional cartilage of the ipsilateral limb.   128 
Histology: Following mechanical testing the specimens were decalcified in formic 129 
acid/sodium citrate over four weeks, prior to routine paraffin processing. Sections of 10 m 130 
thickness were made through the central portion of the defect.  Sections were stained with 131 
Toluidine Blue and Safranin O/Fast Green.  The histology sections were blindly scored by 132 
one investigator, using a modified O’Driscoll score (Table 3).  133 
Immunohistochemistry:   Immunohistochemistry was performed as described previously [26].  134 
The following primary antibodies were used in this study; monoclonal mouse anti human 135 
a) b) c) d) 
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type I collagen (MP Biomedicals, US, 1 in 200 dilution) and monoclonal mouse anti human 136 
type II collagen (MP Biomedicals, US, 1 in 100 dilution). Horseradish peroxidase-conjugated 137 
secondary anti-rabbit and mouse immunoglobulins were used as appropriate, and the colour 138 
reaction developed with 0.1% 3′, 3-diaminobenzidine tetrachloride (DAB)/0.01% hydrogen 139 
peroxide. Normal species-specific serum was used as a control in all experiments.   140 
Analysis of rhFGF-18 concentrations in serum and synovial fluid Blood samples and 141 
synovial fluid from the operated joint were obtained from animals in which 32g rh FGF-18 142 
was administered on the membrane to the chondral defect treated by microfracture (Group 143 
H). Samples were obtained at weekly intervals week 1 – 12. 144 
Synovial fluid samples were analysed using a qualified three step immunoassay sandwich 145 
method performed on a Gyrolab platform. Samples were treated with 20 µg/mL 146 
Hyaluronidase, incubated for 30 minutes at 22±2°C in shaking and centrifuged prior to 147 
dilution with assay buffer and analysis.  A biotinylated mouse monoclonal antibody against 148 
rhFGF-18 (clone F44A2, 0.1 mg/mL, Merck Serono) was used as capture reagent, and an 149 
Alexa Fluor-647 labelled monoclonal antibody against rhFGF-18 (clone F5A2, 20 nM, 150 
Merck Serono) was used as a detection reagent. The specifically-bound analyte was 151 
quantified by laser-induced fluorescence detection.   152 
Statistical analysis:  Statistical significance between groups and within groups for each end 153 
point was determined using a one-way analysis of variance (ANOVA) and Bonferroni's post 154 
hoc test. Where data sets within groups were not found to be normally distributed, a non-155 
parametric Kruskal-Wallis test was instead used, with a post hoc Dunns multiple comparisons 156 
test. GraphPad Prism 5 statistical software package (Graphpad Software Inc, La Jolla, CA) 157 
was used for data analysis.   158 
Results 159 
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Surgery:  The surgical procedures and recovery from surgery was uneventful.  160 
rhFGF-18 concentrations: rhFGF-18 was detected in the synovial fluid of all 5 animals at 161 
week 1 post surgery (mean 3466.44 pg/ml +/- 1735.94 pg/ml).  No rhFGF-18 could be 162 
detected in the synovial fluid after week 1 and no rhFGF-18 was detected in the serum at any 163 
time point. 164 
Force plate analysis: Using a force plate, the peak vertical force of the operated leg was 165 
measured pre and post surgery.  In all operated animals there was a reduction in weight 166 
bearing at 2 weeks post surgery (Fig 1a and b) and then a recovery in weight bearing with 167 
time.   168 
There was a significant difference between weight bearing in animals that received 0g 169 
rhFGF-18 and animals that received 6.4g rhFGF-18 delivered on the membrane at 2 weeks 170 
post-operatively and a significant difference between weight bearing in animals that received 171 
0g rhFGF-18 and animals that received 32g rhFGF-18 delivered on the membrane at 2 and 172 
4 weeks post-operatively i.e. animals that received rhFGF-18 had increased weight bearing 173 
following surgery. No difference was observed between other experimental groups.  174 
Gross morphology:  No adverse effects, for example, osteophyte formation or joint 175 
degeneration was found in any of the animals. The quality of repair at the site of the defect 176 
was assessed using the macroscopic ICRS scoring scale. No significant difference was found 177 
between treatment groups (Fig. 2). 178 
Mechanical testing: At 6m there was no significant difference between the treatment groups, 179 
either between the contralateral limb or the perilesional cartilage in the operated limb (Fig. 3). 180 
Quantitative Histology 181 
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Modified O’Driscoll total histology scores:  All samples were scored using the modified 182 
O’Driscoll score (Fig. 4). No differences were detected between the two control groups (i/a 183 
vehicle injections and membrane applied with no rhFGF-18 added).  The administration of 184 
two cycles of i/a rhFGF-18 significantly improved the modified O’Driscoll score.  In 185 
addition, there was a statistically significant increase in modified O’Driscoll score when 186 
either 6.4µg and 32µg rhFGF-18 were loaded onto the Chondrogide membrane when 187 
compared to controls.  There was no difference between the intra-articular injected rhFGF-18 188 
and 32µg rhFGF-18 loaded onto the membrane at the point of surgery 189 
Histological evaluation and immunohistochemistry In the control sections and those animals 190 
receiving 0.064 and 0.64µg rhFGF-18 there was little evidence of cartilage repair (Fig. 5A), 191 
as indicated by the modified O’Driscoll score. Most of these samples showed no repair, with 192 
denuded subchondral bone still present even at 6 months over much of the damaged zone.  In 193 
contrast, in the membrane + 32µg rhFGF-18 and 30µg rhFGF-18 administered intra-194 
articularly there was evidence of repair tissue with characteristic features of hyaline cartilage 195 
extending over a wider area of the defect with evidence of zonal organisation of the 196 
chondrocytes (Figs 5B and C).  197 
IHC for collagen types I and II was performed  on all of the samples.  In the control samples 198 
interpretation of the results was hampered because little repair tissue was present, so that 199 
there was minimal tissue present to be stained with either antibody. In the presence of both 200 
membrane + 32µg rhFGF-18 and 30µg rhFGF-18, the repair tissue was strongly stained for 201 
type II collagen with minimal type I collagen staining, indicating a mature hyaline-like 202 
cartilage repair tissue had been produced (Figs. 6a-d). 203 
 204 
 205 
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Discussion 206 
This study demonstrates that a combination of microfracture and 32µg rhFGF-18 applied via 207 
a collagen membrane at the point of surgery in a ‘one step cartilage repair’ - results in 208 
significantly improved cartilage repair tissue compared to microfracture, in an ovine chondral 209 
defect model. The results seen were comparable to the administration of two cycles of intra-210 
articular 30µg rhFGF-18 in this study and those previously reported by our group [16]. 211 
In this study significant improvements were detected in weight bearing in the 2 and 4 week 212 
post-operative period and the modified O’Driscoll histology score. In addition, the tissue 213 
produced in the presence of rhFGF18 showed a repair tissue phenotype with features typical 214 
of hyaline cartilage, namely strong type II collagen immunoreactivity and little or no type I 215 
collagen immunoreactivity.  In addition, no adverse events were found either with 216 
administration of rhFGF-18 on the membrane or with the intra-articular administration of the 217 
growth factor, indicating that this treatment does not raise any safety concerns in the joint 218 
environment. 219 
Retention of intra-articular medication within the joint is a separate safety concern. Intra-220 
articular medication enters the circulation via both vascular and lymphatic routes and can 221 
have potentially significant effects [27,28].  In this study no rhFGF-18 was detected in the 222 
systemic circulation in a 12 week experimental period, indicating that the rhFGF-18 was 223 
retained within the joint. In contrast, rhFGF-18 was detected within the synovial fluid of the 224 
treated joint at 1 week post-surgery.  This finding compares favourably with studies of other 225 
intra-articular treatment modalities including hyaluronan [29], autologous conditioned serum 226 
[30] and interleukin-1 receptor antagonist [31], all of whom are detectable in the joint for less 227 
time than detected in this study.  This indicates that the collagen membrane vehicle is likely 228 
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to have retained the rhFGF-18 locally, providing sustained release of the drug, as has been 229 
reported with other growth factors applied to collagen membranes [32,33]. 230 
 231 
The concept of an‘augmented microfracture’ procedure as a one step cartilage repair is an 232 
active area of current research. Recently, enhancement of microfracture techniques by 233 
application of stem cells [25], collagen membranes [34], ECM biomembranes [35] and 234 
chitosan-based BST-CarGel [36] have all shown superior healing compared to microfracture 235 
alone. That the presence of a scaffold or membrane alone leads to increased healing has led to 236 
the suggestion that these additions are stabilising or protecting the blood clots formed by the 237 
microfracture procedure, supporting the healing of the damaged tissue [37].  In this study, in 238 
contrast, we found no difference in any healing outcomes between groups that had 239 
microfracture alone and microfracture plus membrane, indicating that, in this model, 240 
application of the membrane did not provide any protective effect to the repairing tissue.  241 
Significant increases in healing were only detected in the presence of 6.4 and 32µg rhFGF-242 
18.  243 
In this study, three components of healing were examined.  In addition to the standard gross 244 
findings (ICRS score) and histological analysis (modified O’Driscoll score, 245 
immunohistology), we used two functional measures of joint healing, weight bearing and 246 
durometer measurements. Durometer measurements indicate the stiffness of the healed 247 
cartilage relative to the undamaged cartilage.  In this study we did not find a statistically 248 
significant difference between treatment groups, similar to that observed by our group in a 249 
previous, similar study [16].  These results, taken together, indicate that durometer 250 
measurements in this model may be of little functional value perhaps due to the influence of 251 
the underlying bone.  252 
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In contrast, we have demonstrated that animals that received 32µg rhFGF-18, applied on a 253 
membrane at the point of surgery, had significantly increased weight bearing on the operated 254 
leg at weeks 2 and 4 post surgery compared to controls and had returned to pre-operative 255 
levels of weight bearing by week 8 post surgery. The timing of this increased weight bearing 256 
is likely to be too early to be attributed to enhanced healing of the defects and may, perhaps, 257 
indicate that rhFGF-18 might have analgesic actions post surgery.  However, it must be noted 258 
that the sample size used in the study (n=5 per experimental group) was determined using a 259 
power calculation designed to allow differences in histological features, not joint loading. 260 
Further work is needed in this area to establish the validity of the observation and the 261 
mechanisms underlying it.  262 
Improving the quantity and quality of microfracture repair tissue is a clear clinical need [8]. 263 
In this, and a previous study [16], we have observed that rhFGF18 significantly improves the 264 
quality of healing post defect creation, whether applied at the point of surgery or delivered 265 
via intra-articular injection. However, in this study the macroscopic ICRS healing score was 266 
not significantly different between rhFGF-18 i/a and controls, as we have demonstrated 267 
previously. Whilst the mean ICRS score was higher in animals that had received rhFGF-18 268 
i/a  compared to controls, there was a wide variance in the data (all animals were included).  269 
This is likely due to biological variance between animals and reflects the lower number of 270 
animals used in this study (5 compared to 16 per group in the previous study [16],), as noted 271 
for the weight bearing data. Previous data from in vivo damage/repair models [22] and FGF-272 
18 over-expression models [38,39], support the observation that rhFGF-18 drives the 273 
formation of increased and higher quality cartilage in vivo. FGF18 is has ‘anabolic’ effects in 274 
cartilage [40] and work in our group has shown that rhFGF-18 alters ECM metabolism and 275 
also reduces apoptosis in response to damage [41].   FGF-18 has also been shown to have a 276 
13 
 
potential chondroprotective role, possibly via regulation of Tissue Inhibitor of 277 
Metalloproteinases -1 (TIMP-1) [24].  278 
 279 
In conclusion, the administration of rhFGF18 on a collagen membrane significantly enhances 280 
the healing of a microfracture treated cartilage defect. This augmented microfracture 281 
technique should be considered as a potential novel therapy for articular cartilage repair. 282 
Within a clinical setting administration of rhFGF-18 via a membrane to a microfracture 283 
treated lesion would allow a ‘point of service’ application of a novel biological factor that has 284 
demonstrable capacity to enhance cartilage healing. 285 
 286 
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 289 
Table Legends 290 
Table 1: Eight treatment groups were used, with all animals undergoing the microfracture 291 
procedure (n=40 total). Groups C was the control i.e. microfracture only, Groups A and B 292 
had microfracture plus intra-articular injections, Groups D to H had microfracture plus 293 
membrane +/- recombinant human fibroblastic growth factor (rhFGF18).  Duration of 294 
experiment for Groups A to G 6m, Group H, 3m 295 
Table 2: ICRS macroscopic scoring system 296 
Table 3: Modified O’Driscoll scoring system 297 
 298 
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Figure Legends 299 
Fig. 1 Weight bearing in the operated limb as measured using an Accugait force plate. The 300 
results presented are the mean +/- SD of the values for 5 animals per group pre surgery and 301 
2,4,8,12,16 and 20 weeks post surgery. Fig 1A. Weight bearing in animals that had a 302 
microfracture treated chondral defect combined with rhFGF-18 delivered via a collagen 303 
membrane at the point of surgery. There is a significant difference in the weight bearing in 304 
animals that received 32g rhFGF-18 compared to lower concentrations of rhFGF-18 and the 305 
control (0g rhFGF-18) at weeks 2 and 4 post surgery. Fig 1B. Weight bearing in animals 306 
that received 0 or 30g rhFGF18 injected into the medial femoro-tibial joint once a week for 307 
3 weeks at 4, 5 and 6 weeks post-operatively and 16, 17 and 18 weeks post-operatively. 308 
There is no significant difference between the two groups. * = significant difference at this 309 
time point. 310 
 311 
Fig. 2 The effect of rhFGF18 on the total modified ICRS macroscopic score. There is no 312 
statistically significant difference between groups. 313 
 314 
Fig. 3 The effect of rhFGF19 on the stiffness of the repaired cartilage as a percentage of the 315 
contalateral limb. There is no difference between the groups. 316 
 317 
 Fig. 4 The effect of rhFGF18 on the Modified O’Driscoll score. There was a statistically 318 
significant increase in modified O’Driscoll score in the animals treated with intra-articular 319 
30g rhFGF18 (*) and those treated with 6.4g and 32g rhFGF-18 (*) applied on a collagen 320 
membrane at the point of surgery compared to controls and lower doses of rhFGF-18. 321 
 322 
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Fig. 5. Safranin O stained sections. A Control – membrane + 0g rhFGF18.  No hyaline 323 
cartilage is present at the lesion site. B Membrane + 32g rhGFG-18 applied via a membrane 324 
showing good hyaline cartilage production at the lesion site. C Intra-articular 30g rhFGF-18 325 
showing good hyaline cartilage production similar to that seen in B. 326 
 327 
Figure 6. Immunohistochemistry.  Collagen was visualised using a DAB (brown) stain. Figs. 328 
6a and b 2 cycles rhFGF18 at 6 months. Immunohistochemistry of type I and type II 329 
collagen Figs. 6c and d 32g rhGFG applied on bilayer membrane at 6 months. 330 
Immunohistochemistry of type I and type II collagen. In both treatments the repair cartilage is 331 
strongly positive for type II collagen and weakly positive for type I collagen indicating that 332 
the cartilage is similar to hyaline cartilage. 333 
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